AKT1和MAPK8:孕期糖尿病的新目标?
Aysegul Turkyilmaz1, Melike Nur Akin2, Burcu Kasap2
1Faculty of Health Sciences, Department of Nutrition and Dietetics, Mugla Sıtkı Koçman University, Muğla, Turkey.
Fetal and pediatric pathology
|August 23, 2024
概括
孕期糖尿病 (GDM) 涉及AKT1和MAPK8基因的胎盘表达的改变. 这些发现表明这些基因在GDM病理生理学中的潜在作用,并为未来的研究提供了目标.
科学领域:
- 生殖生物学 生殖生物学
- 分子遗传学 分子遗传学
- 内分泌学 在内分泌学.
背景情况:
- 孕期糖尿病 (GDM) 损害了胎盘功能,对母亲和胎儿的健康构成风险.
- 胰岛素耐药性和细胞信号通路都与GDM病变发生有关.
- 在GDM中AKT1和MAPK8基因的作用尚未完全理解.
研究的目的:
- 研究患有GDM的女性胎盘组织中AKT1和MAPK8基因的表达水平.
- 探索使用in silico分析在GDM中改变基因表达的潜在功能影响.
主要方法:
- 实时PCR用于量化来自GDM患者和健康对照者的胎盘样本中的AKT1和MAPK8基因表达.
- 使用in silico方法分析观察到的基因表达变化的功能后果.
主要成果:
- 与对照组相比,在GDM胎盘中观察到AKT1和MAPK8基因表达的显著差异 (分别为p=0.047和p=0.007).
- 在 silico 分析表明了改变基因表达和糖尿病相关的信号通路之间的潜在联系.
结论:
- 这项研究确定AKT1和MAPK8是具有在GDM胎盘中差异表达的基因.
- 这些发现表明AKT1和MAPK8在GDM病理生理学中的潜在作用.
- 对AKT1和MAPK8的功能机制的进一步研究可能会揭示GDM的治疗点.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Pathophysiology of Diabetes
908
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
908
Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306
Dipeptidyl Peptidase 4 Inhibitors
179
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
179
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K


